Due to the fact people that carry the APOE e4 gene variant show up to possess a larger threat of serious complications, the FDA suggests currently being tested to the gene variant before starting treatment with lecanemab or donanemab. The extension research also evaluated CLARITY AD individuals who had a https://toriu865whs5.wikitelevisions.com/user